Eyenovia - PharmaKB

Company Reports

Company Reports

Disease Reports

Disease Reports

Company ReportsEyenovia

Eyenovia

Download report

Favorite

Financial

Marketed Drugs

Clinical Trials

Financial

Stock price

No data

Company Revenue

Quarterly

Quarterly

Annual

Annual

Projections

*Quarterly sales USD (in millions)

Plot placeholder

Mock data
Subscribe for the real data

Revenue by Drug

Marketed Drugs

Therapeutic Areas:

All

Classification:

All

Include Generics:

Trade Name	Drug Name	Approved	Patent Expires	Indication
Mydcombi	Phenylephrine, Tropicamide	2023-05-05	2031-2036	Septic shock , Hypotension , Pruritus ani , Pain , Postoperative pain , Open-angle glaucoma , Fissure in ano , Intraocular lens implantation , Hemorrhoids , Vasomotor rhinitis , Supraventricular tachycardia , Low cardiac output , Bradycardia , Heart arrest , Ventricular fibrillation , Hemorrhagic shock , Torsades de pointes , Adams-stokes syndrome , Pruritus , Allergic conjunctivitis , Allergic rhinitis seasonal , Allergic rhinitis perennial , Photophobia , Inflammation , Keratitis , Iritis , Iridocyclitis , Postoperative complications , Vomiting , Nausea , Anaphylaxis , Urticaria , Motion sickness , Cough , Juvenile arthritis , Menorrhagia , Ankylosing spondylitis , Rheumatoid arthritis , Fever , Osteoarthritis , Bursitis , Dysmenorrhea , Gout , Premenstrual syndrome
Clobetasol	Clobetasol propionate	2024-03-04		—

Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Drug Name

Phase 1

Phase 2

Phase 3

Phase 4

Indication

Phenylephrine hydrochloride

© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use